On April 14, 2020 Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, reported the presentation of new data at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting I, taking place from April 27-28, 2020 (Press release, Ribon Therapeutics, APR 14, 2020, View Source [SID1234556309]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This meeting will feature a selection of high-impact proffered paper presentations, including:

Session: Advances in Cancer Drug Design and Discovery
Abstract ID: 3974
Title: A Potent and Selective PARP14 Inhibitor Decreases Pro-tumor Macrophage Function and Elicits Inflammatory Responses in Tumor Explants
Presenter: Laurie Schenkel, Ph.D.
Date/Time: April 27, 2020, 12:20 p.m. – 12:30 p.m.
Session: New Drugs on the Horizon – Part 2
Abstract ID: DDT02
Title: RBN-2397: A First-in-Class PARP7 Inhibitor Targeting a Newly Discovered Cancer Vulnerability in Stress-Signaling Pathways
Presenter: Melissa Vasbinder, Ph.D.
Date/Time: April 28, 2020, 10:50 a.m. – 11:10 a.m.
AACR Virtual Meeting I the first of two virtual meetings; the second, AACR (Free AACR Whitepaper) Virtual Meeting II, is taking place on June 22-24, 2020.